AstraZeneca Statistics

Total Valuation

AstraZeneca has a market cap or net worth of EUR 187.74 billion. The enterprise value is 211.10 billion.

Market Cap	187.74B
Enterprise Value	211.10B

Important Dates

The next estimated earnings date is Tuesday, April 29, 2025.

Earnings Date	Apr 29, 2025
Ex-Dividend Date	Feb 20, 2025

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+0.06%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.54B

Valuation Ratios

The trailing PE ratio is 27.63.

PE Ratio	27.63
Forward PE	n/a
PS Ratio	3.59
PB Ratio	4.76
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 12.65, with an EV/FCF ratio of 21.99.

EV / Earnings	31.07
EV / Sales	4.18
EV / EBITDA	12.65
EV / EBIT	17.53
EV / FCF	21.99

Financial Position

The company has a current ratio of 0.93, with a Debt / Equity ratio of 0.75.

Current Ratio	0.93
Quick Ratio	0.67
Debt / Equity	0.75
Debt / EBITDA	1.70
Debt / FCF	3.07
Interest Coverage	9.22

Financial Efficiency

Return on equity (ROE) is 17.59% and return on invested capital (ROIC) is 11.53%.

Return on Equity (ROE)	17.59%
Return on Assets (ROA)	7.88%
Return on Invested Capital (ROIC)	11.53%
Return on Capital Employed (ROCE)	16.97%
Revenue Per Employee	553,861
Profits Per Employee	72,058
Employee Count	94,300
Asset Turnover	0.53
Inventory Turnover	1.80

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -7.03% in the last 52 weeks. The beta is 0.25, so AstraZeneca's price volatility has been lower than the market average.

Beta (5Y)	0.25
52-Week Price Change	-7.03%
50-Day Moving Average	135.16
200-Day Moving Average	137.18
Relative Strength Index (RSI)	42.92
Average Volume (20 Days)	25,091

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, AstraZeneca had revenue of EUR 52.23 billion and earned 6.80 billion in profits. Earnings per share was 4.35.

Revenue	52.23B
Gross Profit	42.92B
Operating Income	12.49B
Pretax Income	8.39B
Net Income	6.80B
EBITDA	16.97B
EBIT	12.49B
Earnings Per Share (EPS)	4.35

Full Income Statement

Balance Sheet

The company has 5.34 billion in cash and 29.42 billion in debt, giving a net cash position of -24.08 billion.

Cash & Cash Equivalents	5.34B
Total Debt	29.42B
Net Cash	-24.08B
Net Cash Per Share	n/a
Equity (Book Value)	39.48B
Book Value Per Share	25.41
Working Capital	-1.97B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 11.46 billion and capital expenditures -1.86 billion, giving a free cash flow of 9.60 billion.

Operating Cash Flow	11.46B
Capital Expenditures	-1.86B
Free Cash Flow	9.60B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 82.18%, with operating and profit margins of 23.91% and 13.01%.

Gross Margin	82.18%
Operating Margin	23.91%
Pretax Margin	16.07%
Profit Margin	13.01%
EBITDA Margin	32.49%
EBIT Margin	23.91%
FCF Margin	18.38%

Dividends & Yields

This stock pays an annual dividend of 2.93, which amounts to a dividend yield of 2.47%.

Dividend Per Share	2.93
Dividend Yield	2.47%
Dividend Growth (YoY)	10.55%
Years of Dividend Growth	3
Payout Ratio	65.80%
Buyback Yield	-0.06%
Shareholder Yield	2.41%
Earnings Yield	3.62%
FCF Yield	5.11%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

AstraZeneca has an Altman Z-Score of 3.15.

Altman Z-Score	3.15
Piotroski F-Score	n/a